ArticleAnnals of thoracic medicine
Dasatinib-induced pleural effusion: Chylothorax, an option to consider.
Article in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.Therapeutic innovation & regulatory science · 2026Article
- Case Report: Dasatinib-associated chylothorax and occultFrontiers in pharmacology · 2026Article
- Review
- Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports.Frontiers in pharmacology · 2025Article
- Article
- Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.Translational cancer research · 2023Article
- Dasatinib-Induced Chylothorax Beyond 5 Years of Treatment: Is There Actually Any Limit?European journal of case reports in internal medicine · 2023Article
- Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.The American journal of case reports · 2022Article
- Dasatinib-Induced Bilateral Pleural Effusions.Cureus · 2022Article
- Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia.Respiratory medicine case reports · 2022Article
- A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.Blood research · 2021Review
- Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.Respirology case reports · 2021Article
- Dasatinib-induced chylothorax: report of a case and review of the literature.Investigational new drugs · 2020Review
- Chylothorax: complication attributed to dasatinib use.BMJ case reports · 2019Article
- Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan".Internal medicine (Tokyo, Japan) · 2019Review
- Tyrosine Kinase Inhibitor-associated Fibrothorax.American journal of respiratory and critical care medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib is a drug for treatment of oncogene fusion protein BCR-ABL-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant/intolerant to imatinib. Pleural effusion (PE) is a common adverse effect, and in this context, we present four cases seen due to this cause. One of them is a chylothorax. The PE grade is variable, and the physiopathology is not well established, although a block in T-lymphocyte function or inhibition of platelet-derived growth factor receptor-β is suggested being involved. The PE is generally a lymphocyte-predominant exudate, but can also present as chylothorax. Several factors have been associated with its appearance, particularly the administration in two daily doses. Low grade (1-2) PEs usually respond well to interrupt the treatment while those of higher grade may also require therapeutic thoracentesis and corticosteroids. There are currently no firm guidelines that establish when to resort to one form of treatment or another.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.